3rd Quarter - Report — COHERUS BIOSCIENCES for COHERUS BIOSCIENCES, INC. (2022)

Firm

COHERUS BIOSCIENCES

Client

COHERUS BIOSCIENCES, INC.

Income

—

Expenses

$250,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Build Back Better Act Drug Pricing Reform ASP+8 for biosimilars Domestic Manufacturing Medicare implications on biosimilars Appropriations pertaining to FDA inspections and American Made preferences HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain H.R. 2815 - The BIOSIM Act H.R. 2869 / S. 1427 - Increasing Access to Biosimilars Act of 2021 H.R. 2855 - Star Rating for Biosimilars S. 2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S. 1176 - Onshoring Essential Antibiotics Act S. 1693 - Medical Supplies for Pandemics Act 340B Drug Pricing Program HR 3683 Securing America's Pharmaceutical Supply Chain S 2640 Disease X Act S. 2662 Industrial Finance Corporation Act H.R. 7400 /S. 3991 American Made Pharmaceuticals Act Biosimilar Patient and Provider Education (including Part D) FDA foreign inspections S. 3799 PREVENT Pandemics Act ASPR/BARDA funding and policy H.R. 2870 Essential Medicine Strategic Stockpile Act (EMSSA) H.R. 5376 Inflation Reduction Act

Lobbyist	Covered position, as disclosed
BEN KENNEY	Director of Strategic Communications and Stakeholder Engagement, Centers for Medicare and Medicaid Services (2018-2021), Associate Administrator, General Services Administration (2017-2018), Legislative Aide, U.S. Sen. Daniel R. Coats (2011-2012)
AMANDA MAJOR	—
ALI MCBRIDE New	—
DAVID SANDERS	Legislative Affairs, Dept of Commerce, US Patent and Trademark Office (2005-2007) Legislative Assistant, Representative Marsha Blackburn (2002-2004) Legislative and Press Intern, Senator Fred Thompson (2000)

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); White House Office; Natl Security Council (NSC); Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); SENATE; Executive Office of the President (EOP); Defense, Dept of (DOD)

Bills named: H.R. 2870 (117th), S. 3799 (117th), H.R. 3683 (117th), H.R. 2855 (117th), H.R. 2869 (117th), S. 2662 (117th), H.R. 5376 (117th), S. 2082 (117th), S. 1693 (117th), S. 1176 (117th), H.R. 7400 (117th), S. 1427 (117th), H.R. 2815 (117th), S. 3991 (117th)

Government Issues GOV

Implementation of Buy American and Supply Chain Executive Orders American-Made Policies American-Made Supply Chain Security of the American Pharmaceutical and Medical Supply Chain Drug Pricing Reform Biosimilars Policy BARDA ASPR ARPA-H Industrial Supply and Financing

Lobbyist	Covered position, as disclosed
BEN KENNEY	CMS, HHS
AMANDA MAJOR	—
DAVID SANDERS	—

Contacted: Office of Management & Budget (OMB); White House Office; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.